Trevi Therapeutics, Inc.
Haduvio
chronic cough in patients with non-IPF interstitial lung disease
Countdown
86days
Catalyst readout · ~ Sep 30, 2026 estimated
What's at stake
A key catalyst for Haduvio (chronic cough in patients with non-IPF interstitial lung disease) is expected ~ Sep 30, 2026.
Primary source
· SEC 8-K
verified 13h ago
“The Company expects these cash resources will enable it to fund and report topline data from its planned Phase 2b trial for the treatment of patients with refractory chronic cough,”